AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01947855 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin
Description: Empagliflozin high dose tablet once daily
Study NCT01947855 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo tablet matching Empagliflozin high dose
Study NCT02613273 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental: Arm 1 (Aerobic Exercise)
Description: This periodized program consists of 3 aerobic exercise sessions per week comprised of two high-intensity interval training workouts and 1 continuous vigorous intensity workout.
Study NCT02613273 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental: Arm 2 (Resist. Exercise)
Description: This periodized program consisting of 3 resistance exercise sessions per week comprised of high load/low volume, light load/high volume, and moderate load/moderate volume.
Study NCT02282293 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Monthly dihydroartemisinin-piperaquine (DP) + daily trimethoprim/sulfamethoxazole (TS)
Study NCT02282293 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Monthly placebo + daily trimethoprim/sulfamethoxazole (TS)
Study NCT03927378 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-ketamine
Description: S-ketamine (0.2 mg/kg in 20 ml normal saline) is administered by intravenous infusion in 40 minutes after childbirth.
Study NCT03927378 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (20 ml normal saline) is administered by intravenous infusion in 40 minutes after childbirth.
Study NCT04178278 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Shuttle walking test
Description: Patients will be required to walk around a 10-m course marked by cones placed 9 m apart, thus allowing 0.5 m for turning at each end. Walking speed will be regulated by prerecorded signals on a compact disc or MP3 file. Patients will increase walking speed at every minute. patients can stop this study, when they can not maintain their speeds due to dyspnea
Study NCT04178278 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Exercise stress test
Description: Exercise stress test will be performed with cycle. When patients perform this study, they will gradually increase the velocity. Investigators will measure electrocardiography, vital sign, oxygen saturation, oxygen uptake, minute ventilation and fatigue.
Study NCT04178278 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: 6 minutes walking test
Description: When participants perform 6 minutes walking test, patients will walk around the tract during 6 minutes. They can their walking speed according to condition and symptom. Investigators records walking distance, pulse rate, oxygen saturation and Borg scale
Study NCT02224248 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health checks with fitness testing
Description: Fitness testing as part of a preventive health check compose the intervention in this trial. Thus, the intervention group will receive preventive health checks with fitness testing.
Study NCT02224248 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health checks without fitness testing
Description: The active comparator will not receive fitness testing as part of the preventive health checks. With the exception of fitness testing, the preventive health checks in the active comparator group and the intervention group are identical.
Study NCT02103296 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Drawing admission labs from cord blood
Study NCT02103296 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Drawing admission labs from infant blood
Study NCT04721587 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual Reality
Description: The patients of the VR Group will be subjected to the same hysteroscopy technique as the Standard of Care Group, but additionally a VR device will be applied where a distraction VR environment (Underwater Game) will be reproduced during the exploration
Study NCT02121613 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Permixon® 160 mg
Description: Oral administration - 160 mg twice daily.
Study NCT02121613 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Tamsulosine LP
Description: Oral administration - 0.4 mg daily.
Study NCT02121613 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo matching Permixon® 160 mg
Description: Oral administration - twice daily.
Study NCT02121613 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo matching Permixon® 160 mg
Description: Oral administration - twice daily.
Study NCT02121613 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Placebo matching Permixon® 160 mg
Description: Oral administration - twice daily.
Study NCT02121613 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo matching Tamsulosine LP
Description: Oral administration - daily.
Study NCT02121613 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo matching Tamsulosine LP
Description: Oral administration - daily.
Study NCT02121613 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Placebo matching Tamsulosine LP
Description: Oral administration - daily.
Study NCT02499445 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remifentanil
Description: administering remifentanil for anesthesia maintenance
Study NCT02499445 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sevoflurane 1
Description: administering sevoflurane 1 for anesthesia maintenance
Study NCT02499445 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sevoflurane 2
Description: administering sevoflurane 2 for anesthesia maintenance
Study NCT02499445 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: propofol
Description: administering propofol for anesthesia maintenance
Study NCT02499445 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sufentanil
Description: administering sufentanil for anesthesia maintenance
Study NCT02669485 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: indocyanine green
Description: Injection of indocyanine green and using fluorescence imaging to assess perfusion of bowel before bowel transection and anastomosis
Study NCT02669485 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fluorescence imaging
Study NCT00512057 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: allopurinol
Description: allopurinol 300mg twice a day
Study NCT00512057 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study NCT00348881 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DTaP-HB-PRP~T combined vaccine
Description: 0.5 mL, Intramuscular
Study NCT00348881 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Tritanrix-HepB/Hib™ vaccine
Description: 0.5 mL, Intramuscular
Study NCT00348881 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Oral poliomyelitis vaccine (OPV)
Description: Oral co-administered with study vaccine.
Study NCT00348881 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Oral poliomyelitis vaccine (OPV)
Description: Oral co-administered with study vaccine.
Study NCT00123669 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 500 mg of depot hydroxy-progesterone
Description: An intramuscular injection of 500 mg of depot hydroxy-progesterone 5 to 15 days prior to surgery.
Study NCT01848041 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RVL-1201
Description: RVL-1201 0.1% Ophthalmic Solution
Study NCT01848041 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: RVL-1201 Vehicle Placebo
Description: RVL-1201 Vehicle Placebo
Study NCT03079960 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electrophysiological recording and measurement devices
Description: Externalization of DBS connectors and macroelectrodes for simultaneous STN stimulation LFP recordings by the use of electrophysiological recording and measurement devices.
Study NCT03144609 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: low PEEP
Description: The control group consisted of obese patients mechanically ventilated by a standardized volume-controlled breathing mode with low respiratory volume without alveolar recruitment maneuver and using low values of PEEP up to 4 cm H2O.
Study NCT03144609 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ARM
Description: The experimental groups also consisted of obese patients mechanically ventilated by a volume-controlled breathing mode with low respiratory volume 7 ml/kg ideal body mass, but with alveolar recruitment maneuver performed immediately after induction, followed every 30 minutes during the hemodynamic stable condition under operation.
Study NCT03144609 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: high PEEP
Description: The experimental groups also consisted of obese patients mechanically ventilated by a volume-controlled breathing mode with low respiratory volume 7 ml/kg ideal body mass, but with higher PEEP, provided that the upper limit of 40 cm H20 was not exceeded.
Study NCT03255083 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DS-1205c
Description: DS-1205c 200 mg capsule
Study NCT03255083 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Osimertinib
Description: Osimertinib 80 mg tablet
Study NCT01046409 — intervention group
Intervention type: OTHER
Intervention: Measuring collateral flow
Description: Measuring collateral flow using pressure and/or velocity coronary wire
Study NCT03230019 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: chest tube
Description: VATS with chest tube placement
Study NCT03230019 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: two-lumen catheterization
Description: VATS with two-lumen catheterization long the midclavicular line, second intercostal space
Study NCT03230019 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: two-lumen catheter
Description: central venous catheter(two-lumen 7-Fr-20cm)
Study NCT02997306 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Superior/Medial Running Sutures
Description: Simple interrupted stitches and running (continuous) stitches are the two most frequently used suturing techniques. The erythema secondary to these suturing techniques will be compared by utilizing them side-by-side for closure of post-Moh's surgical defect repair in each patient. This intervention consists of running sutures being used for closure of the Superior/Medial half of the incision, and interrupted sutures being used on the Inferior/Lateral half of the incision.
Study NCT02997306 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Inferior/Lateral Running Sutures
Description: Simple interrupted stitches and running (continuous) stitches are the two most frequently used suturing techniques. The erythema secondary to these suturing techniques will be compared by utilizing them side-by-side for closure of post-Moh's surgical defect repair in each patient. This intervention consists of running sutures being used for closure of the Inferior/Lateral half of the incision, and interrupted sutures being used on the Superior/Medial half of the incision.
Study NCT03207763 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Microneedle Formulation 1
Description: Microneedle patches will be made of solid conical structures made of water-soluble excipients that from the Food and Drug Administration's Generally Recognized as Safe (GRAS) list and/or on the FDA list of inactive ingredients in approved products. The total mass of excipients delivered by placebo microneedle patch will be \<1.5 mg. The adhesive backing component is made from hypoallergenic material (commercial medical tapes designed to adhere to skin).~Microneedle patches will be administered topically by manual application to the skin. The sites of microneedle patch application will be cleaned with an alcohol swab and allowed to dry before the microneedle patch is applied. The microneedle patches will be packaged and provided as single patches.
Study NCT03207763 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Microneedle Formulation 2
Description: Microneedle patches will be made of solid conical structures made of water-soluble excipients that from the Food and Drug Administration's Generally Recognized as Safe (GRAS) list and/or on the FDA list of inactive ingredients in approved products. The ratio of the excipients and excipients used will vary slightly from Formulation 1. The total mass of excipients delivered by placebo microneedle patch will be \<1.5 mg. The adhesive backing component is made from hypoallergenic material (commercial medical tapes designed to adhere to skin).~Microneedle patches will be administered topically by manual application to the skin. The sites of microneedle patch application will be cleaned with an alcohol swab and allowed to dry before the microneedle patch is applied. The microneedle patches will be packaged and provided as single patches.
Study NCT03278067 — intervention group
Intervention type: OTHER
Intervention: Enhanced vaccine safety surveillance
Description: Routinely collected primary care data from up to ten general practices to support passive surveillance. Additionally, this passive surveillance will be enhanced by the use of a customized card-based ADR reporting system.
Study NCT00667108 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin
Description: Gabapentin 250 mg oral capsule 30 minutes prior to bedtime
Study NCT00667108 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin
Description: Gabapentin 500 mg oral capsule 30 minutes prior to bedtime
Study NCT00667108 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matched placebo 30 minutes prior to bedtime
Study NCT03624010 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levosimendan 2.5 mg/ml Injectable Solution
Description: A sterile 2.5 mg/mL concentrate solution that is diluted in 5% Dextrose or 0.9 Normal Saline to achieve a 50 microgram/min solution for infusion
Study NCT01865552 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SB4
Description: SC administration
Study NCT01865552 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: EU sourced Enbrel
Description: SC administration
Study NCT01865552 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EU sourced Enbrel
Description: SC administration
Study NCT01865552 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: US sourced Enbrel
Description: SC administration
Study NCT01865552 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: US sourced Enbrel
Description: SC administration
Study NCT01027806 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Montelukast
Description: 1 pill per day for 4 months
Study NCT01027806 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Montelukast
Description: 1 pill per day for 4 months
Study NCT02923921 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pegilodecakin
Description: Pegilodecakin plus FOLFOX
Study NCT02923921 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FOLFOX
Description: FOLFOX Alone
Study NCT02923921 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFOX
Description: FOLFOX Alone
Study NCT05906290 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multigenerational eHealth Intervention for Grandparents and Grandchildren
Description: Participants in this group will use an online program for 30-45 minutes per week over the course of 2 weeks delivered via smartphone, focusing on increasing physical activity.
Study NCT04591678 — intervention group
Intervention type: DRUG
Intervention: nusinersen
Description: SPINRAZA (nusinersen) is FDA approved to treat spinal muscular atrophy (SMA) through intrathecal injection.
Study NCT03329014 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remimazolam
Description: For induction and maintenance of sedation
Study NCT03329014 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Control arm
Study NCT01680029 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PBASE-system 2.0
Study NCT01326338 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitazoxanide
Description: Nitazoxanide Oral Suspension 100 mg/5 ml for patients aged 1-3 years twice daily for 3 days or Nitazoxanide Oral Suspension 200 mg/10 ml for patients aged 4-11 years twice daily for 3 days
Study NCT01326338 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Nitazoxanide
Description: Nitazoxanide Oral Suspension 100 mg/5 ml for patients aged 1-3 years twice daily for 3 days or Nitazoxanide Oral Suspension 200 mg/10 ml for patients aged 4-11 years twice daily for 3 days
Study NCT04398095 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hypofractionated radiotherapy
Description: Resectable or marginally resectable tumors: preoperative hypofractionated 12x 3 Gy radiotherapy (4 days in a week, three weeks) prescribed on planned target volume (tumor volume + elective margins + setup/error margin) with daily image guidance with cone beam-CT or kV-portal position verification.
Study NCT04398095 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hyperthermia
Description: Deep hyperthermia (Celsius TCS or BSD-2000) according to local protocol combined with radiotherapy, twice a week.
Study NCT04398095 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hypofractionated radiotherapy with boost
Description: Non-resectable/inoperable tumors: definitive hypofractionated 12x 3 Gy radiotherapy prescribed on planned target volume (tumor volume + elective margins + setup/error margin) with simultaneous integrated boost 3.5 Gy per fraction prescribed on boost planned target volume (tumor volume + setup/error margin), 4 days in a week, three weeks.~Radiotherapy with daily image guidance with cone beam-CT or kV-portal position verification.
Study NCT03637088 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Simulated Altitude (FiO2: 15.1%)
Description: Inhalation of deoxygenated air through a altitude simulator (Altitrainer), for approx. 1 hour. given by a facemask.
Study NCT03637088 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Shamed Hypoxia (FiO2: 20.9)
Description: Inhalation of unmodified air through an altitude simulator (Altitrainer) for approximately 1 hour given by a facemask
Study NCT04183361 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: ABR and salivary cortisone testing
Description: Three saliva samples at the workplace will be collected immediately after the morning shift. The first saliva sample was given 3 days (Tuesday) before arrival at the research place, the second sample 2 days (Wednesday) before arrival, and the third sample 1 day (Thursday) before arrival at the research site. One hour before saliva sampling, a respondent should not brush his/her teeth nor eat nor drink. Fifteen minutes prior to sample administration, the subject should rinse his/her mouth with a cold water. Samples will be analyzed using High Performance Liquid Chromatography (HPLC) at the Translational Medicine Division of the Srebrnjak Children's Hospital.~2. Collaboration in the process of assessing hearing health at the research place. The assessment includes: otoscopy, tympanometry and audiometry. Subjects will be tested for auditory evoked brainstem response in only one ear, with a more regular hearing threshold.
Study NCT03856281 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intermittent Pneumatic Compression
Description: Participants administer an intermittent pneumatic compression device in addition to their standard lymphoedema care for a 5 week treatment period
Study NCT01710540 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Metformin GSK 850mg
Description: EVALUATE BIOEQUIVALENCE BETWEEN METFORMIN 850 MG TABLETS MANUFACTURED BY SAVIPHARM J.S.C, VIETNAM AND GLUCOPHAGE® 850 MG TABLETS MANUFACTURED BY MERCK SANTE S.A.S.2, RUE DU PRESSOIR VERT-45400 SEMOY-FRANCE AND BE REGISTERED IN VIETNAM IN HEALTHY, ADULT, HUMAN MALE SUBJECTS UNDER FASTING CONDITION
Study NCT01710540 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Gluocophage 850mg
Description: EVALUATE BIOEQUIVALENCE BETWEEN METFORMIN 850 MG TABLETS MANUFACTURED BY SAVIPHARM J.S.C, VIETNAM AND GLUCOPHAGE® 850 MG TABLETS MANUFACTURED BY MERCK SANTE S.A.S.2, RUE DU PRESSOIR VERT-45400 SEMOY-FRANCE AND BE REGISTERED IN VIETNAM IN HEALTHY, ADULT, HUMAN MALE SUBJECTS UNDER FASTING CONDITION
Study NCT00693082 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: flaxseed
Description: 1 tablespoon a day for first three days, increasing to two tablespoons a day for the next three days. On the 7th day start with 3 tablespoons per day and maintain dose throughout the duration of the study (11 weeks).
Study NCT04432727 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Flexitouch Plus with Cellular Connectivity (FT-CC)
Description: Daily use of FT-CC
Study NCT02697344 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given PO
Study NCT02697344 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02697344 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Given PO
Study NCT02697344 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT02697344 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: R-(-)-Gossypol Acetic Acid
Description: Given PO